Merck, Pfizer well-placed for spinoff benefits

U.S. investors have been pressuring companies to return cash to shareholders via spinoffs, and Goldman Sachs points to Merck ($MRK) and Pfizer ($PFE) as two firms that could benefit most from asset sales. Pfizer is exploring options for its animal health and nutritionals businesses. Report